Physician profile
Mark Jonathan Ramos
NPI 1336339811
$29,477.95
in general payments reported to CMS, 2019-2025
33 companies · $775 in 2025
The $775 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $2,916 · 2021: $134 · 2022: $3,324 · 2023: $6,737 · 2024: $3,528 · 2025: $775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,696 · Food and Beverage: $2,441 · Consulting Fee: $1,800 · Travel and Lodging: $85.50 · Education: $17.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,696.00 |
| Food and Beverage | $2,440.80 |
| Consulting Fee | $1,800.00 |
| Travel and Lodging | $85.50 |
| Education | $17.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $14,742.54 | 2019-2024 | Eliquis, Camzyos |
| Amgen INC. | $11,667.60 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $598.23 | 2019-2024 | Lifevest |
| Novartis Pharmaceuticals Corporation | $291.85 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $262.84 | 2023-2025 | Verquvo, Capvaxive |
| Irhythm Technologies, INC. | $193.78 | 2021-2023 | Zio Xt Patch |
| Janssen Pharmaceuticals, INC | $178.86 | 2019-2024 | Xarelto |
| Abbott Laboratories | $164.65 | 2022-2024 | Merlin@Home |
| Pfizer INC. | $159.03 | 2023-2025 | |
| Biotronik INC. | $152.00 | 2023 | Biomonitor |
| Teva Pharmaceuticals USA, INC. | $109.67 | 2022 | |
| Alnylam Pharmaceuticals INC. | $92.54 | 2023-2025 | Onpattro |
| Philips North America LLC | $82.49 | 2023-2024 | (Ck7) Extended Holter |
| Boston Scientific Corporation | $77.85 | 2023-2025 | Watchman Access System, Wavewriter Alpha Prime 16, Watchman Flx |
| Regeneron Healthcare Solutions, INC. | $73.14 | 2023-2025 | Evkeeza |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $69.79 | 2023 | Optimizer |
| Scpharmaceuticals INC. | $65.62 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $62.16 | 2021-2025 | Lokelma, Wainua |
| Azurity Pharmaceuticals, INC. | $60.83 | 2023-2025 | Edarbi, Edarbi, Horizant |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.30 | 2023-2025 | Jardiance |
| Bridgebio Pharma, INC. | $38.05 | 2025 | Attruby |
| Actelion Pharmaceuticals US, INC. | $34.96 | 2024-2025 | Opsumit, Uptravi |
| Kiniksa Pharmaceuticals International, Plc | $34.94 | 2024 | Arcalyst |
| Kestra Medical Technology Services, INC. | $28.14 | 2023 | Assure Wcd |
| Sanofi-Aventis U.S. LLC | $24.76 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $24.40 | 2023 | |
| Exact Sciences Corporation | $23.05 | 2023 | Cologuard Collection Kit |
| Cvrx, INC. | $21.48 | 2023 | Barostim Neo System |
| Kiniksa Pharmaceuticals, Ltd. | $19.23 | 2023 | Arcalyst |
| Cardiva Medical, INC. | $18.75 | 2022 | |
| Altathera Pharmaceuticals LLC | $17.24 | 2025 | Sotalol Hydrochloride |
| Lilly USA, LLC | $17.04 | 2024 | Mounjaro, Zepbound |
| Getinge USA Sales, LLC | $11.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Ramos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.